Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?

Psychiatry Res. 1985 May;15(1):41-8. doi: 10.1016/0165-1781(85)90038-1.

Abstract

The specific binding of the dopamine antagonist 3H-spiperone to lymphocytes from a healthy control group (n = 40), a group of acute, unmedicated schizophrenic patients (n = 27), and a psychiatric control group (n = 16) was investigated. There were no differences in binding parameters between the healthy controls (Bmax 2.6 +/- 0.7 fmoles/10(6) cells; Kd 0.17 +/- 0.07 nM) and the psychiatric control group. Binding capacity of 3H-spiperone was significantly increased in lymphocytes from the schizophrenic patients (Bmax 14.4 +/- 9.3 fmoles/10(6) cells). Moreover, a slight decrease in affinity was observed (Kd 0.44 +/- 0.21 nM). Because the increase in binding appeared only in schizophrenic patients, this peripheral model could prove valuable as a diagnostic criterion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adult
  • B-Lymphocytes / metabolism
  • Binding Sites
  • Butaclamol / metabolism
  • Butyrophenones / metabolism*
  • Female
  • Humans
  • Lymphocytes / metabolism*
  • Male
  • Schizophrenia / blood*
  • Spiperone / metabolism*
  • T-Lymphocytes / metabolism

Substances

  • Butyrophenones
  • Spiperone
  • Butaclamol